SDP Oncology Announces New Data from Phase 1 Solid Tumor Study

September 25, 2020

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) and BioUtah member recently announced new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903) in patients with advanced solid tumors. 

“These preliminary data presented at ESMO 2020 are encouraging as we learn more about how dubermatinib may inhibit the AXL kinase protein and sensitize cancer cells to treatment with other targeted agents in patients with advanced solid tumors,” said David J. Bearss, Ph.D., Chief Scientific Officer and Global Head of Research, SDP Oncology.

“This is an impressive development,” said Kelvyn Cullimore, president and CEO of BioUtah. “SDP Oncology is offering new hope for many cancer patients. We look forward to following the study as it advances.” 

These results were presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress held September 19-21. Preliminary findings showed that dubermatinib, as a single agent and as part of the combination regimens, was well-tolerated with a manageable safety profile.